Additional file 2 of Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment

Additional file 2: Table S2. Compounds with an oral bioavailability value greater than 30%. Table S3. Compounds with a Caco-2 value > − 0.4. Table S4. Compounds with a drug-likeness value > 0.18. Table S5. Compound with a half-life > 3 h . Table S6. The potentially bioactive compounds of YGL capsule using the ADME in silico integrative model.附加文件2：表S2。口服生物利用度（oral bioavailability）大于30%的化合物。表S3：Caco-2值大于−0.4的化合物。表S4：类药性（drug-likeness）值大于0.18的化合物。表S5：半衰期（half-life）大于3小时的化合物。表S6：采用吸收、分布、代谢、排泄（ADME）虚拟整合模型筛选得到的YGL胶囊潜在生物活性化合物。